A Glucose-Powered Device Restored Insulin Production and Reduced Inflammation in Diabetes Models
Researchers developed an implantable device that uses the body's own glucose to power immune-regulating signals. In animal studies, it helped restore pancreatic function and improved blood sugar control in both Type 1 and Type 2 diabetes.
Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.
Key takeaways
- Scientists created an artificial neuroimmune axis (NeuroAxis)—a glucose-powered implant that works without batteries or wireless power
- In Type 1 diabetes rat models, the device promoted recovery of insulin-producing beta cells and reduced inflammatory immune responses
- In Type 2 diabetes rat models, it reduced chronic inflammation and improved how immune cells function
- Animals treated with NeuroAxis showed improved insulin sensitivity and normalized blood sugar control that persisted after treatment ended
- This is early-stage research in animals; human safety and effectiveness remain unknown
What is the artificial neuroimmune axis?
Researchers at Nature published findings on a novel device called NeuroAxis that aims to treat metabolic disorders by restoring balance between the immune system and metabolism. The device is powered entirely by glucose in the body—no batteries, no wireless charging needed.
The NeuroAxis mimics how the vagus nerve naturally sends signals to regulate immune function and metabolism. It operates as a closed-loop system, meaning it can sense glucose levels and adjust its immune-regulating signals in response, similar to how the body's own nervous system works.
How did it perform in Type 1 diabetes models?
In rats with Type 1 diabetes, the NeuroAxis device promoted recovery of insulin-producing beta cells in the pancreas. It also reduced inflammatory immune responses—the overactive immune activity that characterizes Type 1 diabetes.
Animals treated with the device showed restored glucose tolerance and improved insulin sensitivity, with benefits that continued even after the treatment period ended.
What about Type 2 diabetes models?
In rats with Type 2 diabetes, NeuroAxis worked through a different mechanism: it helped remodel macrophages, a type of immune cell, and reduced systemic chronic inflammation. This addresses a key driver of Type 2 diabetes—long-term inflammatory conditions that impair insulin function.
These animals also showed improved insulin sensitivity and normalized blood sugar control following treatment.
What does this mean for patients?
This research is early-stage, conducted only in animal models. While the results are encouraging, there is no evidence yet that NeuroAxis will be safe or effective in people.
The approach represents a novel idea: using the body's own glucose as a power source to regulate immune-metabolic communication. If further research supports these findings, devices like this could one day offer a new treatment avenue for both Type 1 and Type 2 diabetes by addressing inflammation and immune dysfunction at their source.
Evidence label
Source: Nature. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.
Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.
From Type1Cure
Our own writing on the same ground.
- OriginalType 1 diabetes device safety watch: latest FDA recall signals families should reviewA focused safety brief from the current FDA device recall lane, prioritizing CGM, pump, insulin-delivery, glucose-monitoring, and related diabetes-device records.
- OriginalType 1 diabetes device safety watch: latest FDA recall signals families should reviewA focused safety brief from the current FDA device recall lane, prioritizing CGM, pump, insulin-delivery, glucose-monitoring, and related diabetes-device records.
- OriginalType 1 diabetes device safety watch: latest FDA recall signals families should reviewA focused safety brief from the current FDA device recall lane, prioritizing CGM, pump, insulin-delivery, glucose-monitoring, and related diabetes-device records.
Related reading
More evidence-labeled coverage across the Type1Cure library.
- Research summaryCauses & What We KnowPregnant Women with Diabetes Show Higher Rates of Toxoplasma InfectionPubMed indexed literature
- Research summaryCauses & What We KnowExploring Rare Breast Inflammation: What BRCA Mutations and Type 1 Diabetes May SharePubMed indexed literature
- Research summaryCauses & What We KnowUnderstanding Type 1 Diabetes: A Shift Toward Early InterventionPubMed indexed literature
- Research summaryCauses & What We KnowHow Nutrition, Metabolism, and Immunity Connect: What the Lectin Pathway Tells UsPubMed indexed literature
- Research summaryCauses & What We KnowHow Gut Bacteria May Influence the Intestinal Barrier in Type 1 DiabetesPubMed indexed literature
- Research summaryCauses & What We KnowLiver Changes in Cystic Fibrosis: What a New Study FoundPubMed indexed literature